Publications by authors named "Filippo Farnia"
Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.
View Article and Find Full Text PDFAcute kidney injury (AKI) is associated with increased mortality in most critical settings. However, it is unclear whether its mild form (i.e.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to determine how pre-existing diabetes, newly-diagnosed diabetes, and high blood sugar at admission impacted the severity of COVID-19 in hospitalized patients.
- Researchers reviewed the medical records of 413 COVID-19 patients from an outbreak hospital in Italy, finding that those with diabetes had a significantly higher chance of serious outcomes like ICU admission or death.
- Newly-diagnosed diabetes and high glucose levels at admission were found to be particularly strong predictors of worsening COVID-19, primarily due to rapid deterioration in respiratory function.